Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Overview of Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) is a globally recognized contract research organization (CRO) that provides essential services to pharmaceutical, biotechnology, academic, and government clients. The company specializes in supporting the discovery, development, and safe manufacturing of new therapies, playing a pivotal role in the life sciences ecosystem. With a comprehensive portfolio of products and services, CRL helps its clients accelerate research timelines and optimize the drug development process, making it a critical partner in the creation of innovative treatments for patients worldwide.
Core Business Areas
Charles River Laboratories operates across several key business segments, each tailored to meet the diverse needs of its clients:
- Discovery and Early-Stage Development: CRL provides services that span the early phases of drug discovery, including target identification, validation, and preclinical testing. These services are designed to help clients identify viable drug candidates efficiently.
- Safety Assessment: The company offers toxicology and safety evaluation services to ensure that new therapies meet regulatory requirements and are safe for further development.
- Research Models and Services: CRL supplies high-quality research models, including genetically engineered models, as well as associated services to support in vivo research.
- Manufacturing Support: The company provides services such as microbial detection, biopharmaceutical testing, and cell and gene therapy manufacturing support, which are critical for ensuring the quality and safety of therapeutic products.
Market Position and Industry Context
Operating at the intersection of biotechnology, pharmaceuticals, and academic research, Charles River Laboratories serves a growing market driven by the increasing complexity and cost of drug development. The rise of precision medicine, biologics, and cell and gene therapies has further expanded the demand for specialized CRO services. CRL differentiates itself through its end-to-end service offerings, global infrastructure, and expertise in early-stage research, making it a preferred partner for organizations looking to outsource R&D activities. Its ability to integrate discovery, safety assessment, and manufacturing support under one roof provides a seamless experience for clients, reducing time-to-market for new therapies.
Competitive Landscape
Charles River Laboratories faces competition from other CROs such as Labcorp Drug Development, ICON plc, and PPD. However, its focus on early-stage research, coupled with a broad service portfolio and a strong reputation for scientific expertise, sets it apart. The company's investments in technology, innovation, and global infrastructure further strengthen its competitive position, enabling it to address the evolving needs of the life sciences industry.
Significance in the Life Sciences Ecosystem
As a trusted partner to pharmaceutical and biotechnology companies, Charles River Laboratories plays a crucial role in advancing medical innovation. By providing specialized expertise and resources, the company helps its clients navigate the complexities of drug development, ensuring that new therapies reach patients more efficiently. This makes CRL an indispensable player in the global effort to improve healthcare outcomes.
Charles River Laboratories (NYSE: CRL) and ASC Therapeutics have expanded their partnership to manufacture ASC618, a second-generation gene therapy targeting hemophilia A. This collaboration leverages Charles River's expertise in Good Manufacturing Practice (GMP) for virus production established since 2019. ASC618 aims to deliver a modified version of the F8 gene to treat hemophilia A, following ASC Therapeutics' receipt of IND clearance and key regulatory designations in the U.S. and Europe. The partnership underscores a strong relationship built on trust and shared objectives for therapeutic development.
Charles River Laboratories (NYSE: CRL) will present at the Jefferies Healthcare Conference on June 8 at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on June 9 at 10:40 a.m. CT (11:40 a.m. ET). The presentations will cover the company's strategic focus and recent business developments. Live webcasts will be available on the Investor Relations section of the Charles River website, with replays accessible for two weeks after each event.
Charles River supports drug development for biotech and pharmaceutical sectors globally.
Charles River Laboratories (CRL) reported a strong performance for Q1 2022, with revenues reaching $913.9 million, marking a 10.8% increase year-over-year. Adjusted earnings per share (EPS) stood at $2.75, up 8.7% from the previous year. Key growth was driven by acquisitions (4.7% contribution) and organic growth of 9.4%. However, revenue was negatively impacted by foreign currency translation and divestitures. The company updated its 2022 guidance, raising reported revenue growth expectations to 13.5% - 15.5%.
Charles River Laboratories (NYSE: CRL) and Valo Health have launched Logica™, an AI-powered drug discovery solution that combines biological insights with optimized preclinical assets. This integrated offering leverages Valo's Opal Computational Platform and Charles River's expertise to streamline drug discovery. Logica features Advanceable Lead (Logica-AL™) and Candidate (Logica-C™) programs, targeting a 90% success rate in lead series and delivering development candidates 58% of the time. The collaboration marks a significant step forward in drug development, focusing on client value generation.
Charles River Laboratories (CRL) will release its first-quarter 2022 financial results on May 4, before market opening. A conference call to discuss these results is scheduled for the same day at 9:30 a.m. ET. Investors can access the live webcast through the Investor Relations section on CRL's website. The company offers key products and services aimed at accelerating research and drug development for pharmaceutical and biotech sectors.
Charles River Laboratories International, Inc. (NYSE: CRL) has published its 2021 Corporate Citizenship Report, highlighting ESG commitments and initiatives. The report emphasizes leadership accountability, employee engagement through global Resource Groups, community investments, and significant reductions in greenhouse gas emissions. Notably, the company aims for 100% renewable electricity across facilities by 2023. The report adheres to SASB and GRI standards, showcasing Charles River's dedication to corporate responsibility.
Charles River Laboratories (CRL) has acquired Explora BioLabs for approximately $295 million in cash, enhancing its Charles River Accelerator and Development Lab (CRADL™) footprint. This acquisition adds over 15 vivarium facilities across key biohubs like Southern California, San Francisco, and Boston, with plans for expansion in Seattle. Explora BioLabs had an annual revenue of $38 million in 2021, with expected strong growth. The acquisition is projected to be slightly accretive to non-GAAP earnings per share starting in 2023.
Charles River Laboratories (NYSE: CRL) announced the appointment of Flavia H. Pease as the new Chief Financial Officer, effective April 25. She succeeds David R. Smith, who plans to retire. Pease brings over 20 years of experience from Johnson & Johnson, where she served as Vice President and Group CFO of the Medical Devices business, which generated annual revenues of $27 billion in 2021. She is expected to assume the CFO role after the filing of the Company’s 10-Q in early May 2022. Smith will transition to Senior Financial Advisor until February 2023.
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter revenue of $905.1 million, a 14.4% increase year-over-year, and full-year revenue of $3.54 billion. Fourth-quarter GAAP EPS was $2.67, a 5.0% decline, while non-GAAP EPS rose 4.2% to $2.49.
The company reaffirmed its 2022 guidance, anticipating low-teens revenue growth driven by robust client demand. Significant contributions came from the Manufacturing segment, with revenues rising 47.4% in Q4. Despite challenges including the RMS Japan divestiture, CRL's portfolio growth remains strong.
Charles River Laboratories (NYSE: CRL) has secured a wind energy contract with Repsol, aiming to meet all of its European electricity needs through renewable sources by 2023. This virtual power purchase agreement (VPPA) encompasses 30.5 megawatts of wind energy, equating to reduced carbon emissions from over 28,000 homes. This initiative aligns with Charles River's sustainability targets, which also include a solar contract in North America. Together, these efforts will contribute to 90% of the company’s global electricity being sourced from renewables by 2023.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
What does Charles River Laboratories International, Inc. do?
What industries does Charles River Laboratories serve?
How does Charles River Laboratories generate revenue?
What sets Charles River Laboratories apart from competitors?
What role does Charles River Laboratories play in drug development?
Who are the competitors of Charles River Laboratories?
What are Charles River Laboratories' core business segments?
Why is outsourcing to CROs like Charles River Laboratories important?
